Merck delivered a better-than-expected fourth quarter on Tuesday, with its blockbuster cancer drug Keytruda continuing to power results. But the victory lap was cut short as the pharmaceutical giant issued 2026 guidance that fell meaningfully below Wall Street expectations, highlighting the mounting challenges facing one of America's largest drugmakers.

The company reported fourth-quarter revenue of $16.4 billion, topping analyst estimates, while adjusted earnings of $2.04 per share exceeded the consensus forecast of $2.01. Keytruda, the immunotherapy that has become the world's best-selling drug, continued its dominant performance with strong demand across oncology indications.

The Guidance Gap That Spooked Investors

Despite the solid quarter, Merck's forward-looking numbers sent a different message. The company projected 2026 revenue between $65.5 billion and $67 billion, falling short of the $67.6 billion analysts had anticipated. Even more concerning, Merck guided adjusted earnings to $5.00 to $5.15 per share, well below the Street's $5.36 estimate.

A significant portion of the earnings shortfall stems from a one-time charge of approximately $9 billion, or about $3.65 per share, related to Merck's acquisition of Cidara, a biotech company developing a flu prevention drug. While such charges are often excluded from ongoing profitability assessments, the size of the hit underscores the costly efforts Merck is making to diversify its revenue base.

"We continue to execute on our strategy to drive sustainable growth while positioning the company for long-term success," said CEO Rob Davis. "Our pipeline is advancing, and we're making strategic investments to ensure Merck remains a leader in innovative medicine."

— Rob Davis, Merck CEO

The Keytruda Conundrum

Keytruda's success has been both a blessing and a looming challenge. The cancer treatment generated the lion's share of Merck's pharmaceutical revenue, but its U.S. patent expires in 2028, threatening to unleash generic competition that could dramatically erode sales. Management has indicated potential patent runway extension through late 2029, but the clock is ticking.

To prepare for this patent cliff, Merck has embarked on an aggressive cost-cutting program targeting $3 billion in savings by the end of 2027. The company has also been actively acquiring pipeline assets, including the Cidara deal, to build out its portfolio of next-generation therapies.

Gardasil's China Problem

Adding to investor concerns, Merck's HPV vaccine Gardasil reported sales of $1.03 billion for the quarter, down a striking 34% from the prior year period. The decline was driven primarily by lower demand in China, where the vaccine market has become increasingly competitive and price-sensitive.

The China weakness in Gardasil represents a broader theme facing multinational pharmaceutical companies: the world's second-largest economy, once viewed as a growth engine, has become a source of volatility and margin pressure.

Bright Spots in the Portfolio

Not everything in Merck's report was concerning. The company's animal health division posted revenue of nearly $1.51 billion, up 8% year-over-year, demonstrating strength in vaccines and medicines for companion animals and livestock. Management has highlighted this business as an important diversification play that provides stable cash flows.

Additionally, Merck pointed to a robust pipeline with approximately $70 billion in revenue opportunity through the mid-2030s. New product launches and label expansions for existing drugs are expected to help offset some of the Keytruda erosion, though the magnitude and timing remain uncertain.

What It Means for Investors

Merck's results illustrate the delicate balancing act facing large pharmaceutical companies. Current products are performing well, but the industry's dependence on patent-protected blockbusters creates predictable crises that require billions in R&D and M&A spending to address.

For investors, the key question is whether Merck's $70 billion pipeline opportunity can materialize quickly enough to prevent a meaningful earnings trough in the 2028-2030 period. The company's track record suggests it can navigate patent cliffs, having done so successfully before, but the Keytruda transition represents its largest challenge yet.

With Merck shares having gained 13% over the past year, the stock's valuation already reflects considerable optimism about the company's ability to execute. Tuesday's guidance miss serves as a reminder that even the most dominant franchises eventually face mortality, and the market is now pricing in a more cautious path forward.